In a Facebook Live interview from Cape Town, South Africa earlier this week, we heard from NIH's Dr. Carl Dieffenbach about the exciting launch of HVTN 702, a new HIV vaccine clinical trial supported by NIH. The first HIV vaccine efficacy study to launch anywhere in seven years, HVTN 702 is testing whether an experimental vaccine regimen safely prevents HIV infection among South African adults.
Read more about the HVTN 702 trial.
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy